Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | NOL3 |
| Gene Name: | NOL3 |
| Protein Full Name: | Nucleolar protein 3 |
| Alias: | Apoptosis repressor ARC; Apoptosis repressor with CARD; Apoptosis repressor with CARD domain; Apoptosis repressor with caspase recruitment domain (CARD); CARD2; Muscle-enriched cytoplasmic protein; Myp; NOL3; Nop30; Nucleolar protein of 30 kDa |
| Mass (Da): | 24309 |
| Number AA: | 219 |
| UniProt ID: | O60936 |
| Locus ID: | 8996 |
| COSMIC ID: | NOL3 |
| Gene location on chromosome: | 16q22.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19718 |
| Percent of cancer specimens with mutations: | 0.01 |
| Mutations observed as inherited: | NA |
| Found in amplified chromosomal regions in human cancers: | NA |
| Deregulated in translocations: | NA |
| Deregulated by viral insertion: | NA |
| Transduced into viral genome: | NA |
| Gene undergoes hypermethylation: | NA |
| Normal role description: | NOL3, depending on its isoform, can play a role in RNA splicing or inhibiting apoptosis. It may inhibit apoptosis by binding to and inhibiting caspase-8 activity and/or depressing p53 activity. Overexpression of NOL3 has been associated with increased resistance to chemotherapy and radiation. |